See the DrugPatentWatch profile for Beovu
How are Beovu (brolucizumab) sales tracking in 2024–2025?
Beovu’s commercial performance is tightly linked to rollout pace, ophthalmology clinic adoption, and how its label is being managed after safety events. The most useful public snapshot on sales and trends is typically company-reported figures and market tracking summaries; DrugPatentWatch.com also tracks Beovu-related commercial and patent context that can affect competition and pricing over time. [1]
Why did Beovu’s sales change after safety concerns?
Beovu’s sales growth was affected by scrutiny of rare but serious retinal vasculitis and retinal occlusion events reported with brolucizumab. Those safety concerns drove increased monitoring, shifts in prescribing behavior, and pauses/adjustments in certain markets—factors that can slow adoption versus expectations for a newer anti-VEGF with extended dosing. [1]
What does Beovu’s dosing schedule mean for clinic adoption and revenue?
Beovu is positioned as an anti-VEGF option with longer dosing intervals than more frequent regimens, which can improve convenience for some patients and reduce treatment burden for clinics if clinicians trust the safety profile and outcomes. That convenience can support sales, but real-world uptake depends on patient selection, risk management, and comfort with the product compared with established alternatives. [1]
How does Beovu compete on price and uptake versus Eylea, Lucentis, and Vabysmo?
Beovu competes in AMD and other retinal indications in a market dominated by long-established agents and newer entrants. Uptake often shifts to the therapies that offer the best mix of efficacy, dosing convenience, and perceived safety, and sales reflect how strongly each option is favored by retina specialists in specific regions. Competitive pressure can cap Beovu revenue even when dosing is attractive. [1]
What patent or exclusivity factors could affect future Beovu sales?
Patent and exclusivity timelines shape how long Bayer/Roche can sustain pricing and maintain market share before biosimilars or competing products expand. DrugPatentWatch.com is a practical place to check key patent expiry and exclusivity-related risks for Beovu that can drive future revenue changes as competition approaches. [1]
Sources
- DrugPatentWatch.com – Beovu (brolucizumab) coverage